Pasar al contenido principal

DISRUPCION DE LA BARRERA HAMATOENCEFALICA POR ANGIOGENESIS NO PRODUCTIVA EN LA ENFERMEDAD DE ALZHEIMER

PID2021-126894OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Microglia mitochondrial complex I deficiency during development induces glial dysfunction and early lethality

  • Mora-Romero, Bella
  • Capelo-Carrasco, Nicolas
  • Pérez-Moreno, Juan J.
  • Álvarez-Vergara, María I.
  • Trujillo-Estrada, Laura
  • Romero-Molina, Carmen
  • Romero-Molina, Carmen
  • Morano-Catalan, Noelia
  • Vizuete, Marisa
  • López-Barneo, José
  • Nieto-González, J.
  • García-Junco-Clemente, Pablo
  • Vitorica, Javier
  • Gutiérrez, Antonia
  • Macías, David
  • Rosales-Nieves, Alicia E.
  • Pascual Bravo, Alberto
Primary mitochondrial diseases (PMDs) are associated with pediatric neurological disorders and are traditionally related to oxidative phosphorylation system (OXPHOS) defects in neurons. Interestingly, both PMD mouse models and patients with PMD show gliosis, and pharmacological depletion of microglia, the innate immune cells of the brain, ameliorates multiple symptoms in a mouse model. Given that microglia activation correlates with the expression of OXPHOS genes, we studied whether OXPHOS deficits in microglia may contribute to PMDs. We first observed that the metabolic rewiring associated with microglia stimulation in vitro (via IL-33 or TAU treatment) was partially changed by complex I (CI) inhibition (via rotenone treatment). In vivo, we generated a mouse model deficient for CI activity in microglia (MGcCI). MGcCI microglia showed metabolic rewiring and gradual transcriptional activation, which led to hypertrophy and dysfunction in juvenile (1-month-old) and adult (3-month-old) stages, respectively. MGcCI mice presented widespread reactive astrocytes, a decrease of synaptic markers accompanied by an increased number of parvalbumin neurons, a behavioral deficit characterized by prolonged periods of immobility, loss of weight and premature death that was partially rescued by pharmacologic depletion of microglia. Our data demonstrate that microglia development depends on mitochondrial CI and suggest a direct microglial contribution to PMDs., B.M.-R. was the recipient of a ‘Junta de Andalucía’ predoctoral fellowship (2021), N.C.-C., M.I.A.-V. and E.M.M. were each the recipients of an FPU/FPI fellowship from the Spanish Ministry of Education (FPU20/03320, FPU15/02898 and PRE2019-087729) and J.J.P.-M. and A.E.R.-N. were the recipients of JdlC-I and JdlC-F fellowships from MCIN/AEI/ 10.13039/501100011033 (IJC2019-038819-I and FJCI-2015-23708). A.E.R.N. is funded by VII PPIT-US. This work was supported by grants to A.P., J.V., A.G. and D.M. by MCIN/AEI/ 10.13039/501100011033, ISCIII (FORT23/00008 (to A.P.); PI21/00915 (to J.V.); and PI21/00915 (to A.G.), and FEDER (RTI2018-096629-B-100, PID2021-126894OB-I00 ‘y por FEDER Una manera de hacer Europa’, SAF2017-90794-REDT, and PIE13/0004), by the regional Government of Andalusia (‘Proyectos de Excelencia’ P12‐CTS‐2138, P20_01312; BIOT22_00018_1, and ProyExcel_00845) co-funded by CEC, REC_EU and FEDER funds, and by the ‘Ayuda de Biomedicina 2018’, Fundación Domingo Martínez., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Inactivation of the PHD3-FOXO3 axis blunts the type I interferon response in microglia and ameliorates Alzheimer's disease progression

  • Sánchez García, Manuel A.
  • Lara-Ureña, Nieves
  • March Díaz, Rosana
  • Ortega de San Luis, Clara
  • Quiñones-Cañete, Silvia
  • Mora-Romero, Bella
  • Barba-Reyes, Juan M.
  • Cabello-Rivera, Daniel
  • Romero-Molina, Carmen
  • Heras-Garvin, Antonio
  • Navarro-Garrido, Victoria
  • López-Barneo, José
  • Vizuete, Marisa
  • Vitorica, Javier
  • Muñoz-Cabello, Ana M.
  • Muñoz-Manchado, Ana B.
  • Cokman, Matthew E
  • Rosales-Nieves, Alicia E.
  • Pascual Bravo, Alberto
Microglia respond to Alzheimer’s disease (AD) with varied transcriptional responses. We show that oligomeric Aß (oAß) induces the expression of Hif1a and Egln3 in microglia in vitro, together with the transcription of the type I interferon signature (IFNS) genes in a PHD3-dependent manner. We identify FOXO3 as a repressor of IFNS, whose abundance decreases upon PHD3 induction in response to oAß. In vivo, loss of PHD3 correlates with abrogation of the IFNS and activation of the disease-associated microglia signature, an increase in microglia proximity to Aß plaques and phagocytosis of both Aß and small plaques. PHD3 deficiency mitigated the Aß plaque–associated neuropathology and rescued behavioral deficits of an AD mouse model. Last, we demonstrate that microglial PHD3 overexpression in the absence of Aß pathology is sufficient to induce the IFNS and behavioral alterations. Together, our data strongly indicate that the inactivation of the PHD3-FOXO3 axis controls the microglial IFNS in a cell autonomous manner, improving AD outcome., This work was supported by grants to A.P., J.V., A.M.M.-C., and A.B.M.-M. by MCIN/AEI/10.13039/501100011033 and ERDF/EU, ISCIII (FORT23/00008 to A.P. and PI21/00915 to J.V.), and FEDER (RTI2018-096629-B-100, PID2021-126894OB-I00, PID2019-109046GA-I00, and PID2022-136526OB-I00; and “FEDER Una manera de hacer Europa,” SAF2017-90794-REDT, and PIE13/0004); by the regional Government of Andalucia (“Proyectos de Excelencia” P12-CTS-2138, P20_01312; Biotechnology Plan applied to Health PRTR-C17.I1; FEDER Andalucia 2014-2020, US-1261055) co-funded by CEC, REC_EU, and FEDER funds; and by the “Ayuda de Biomedicina 2018,” Fundación Domingo Martínez; and to M.E.C. by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001501), the UK Medical Research Council (FC001501), and the Wellcome Trust (FC001501). R.M.-D. was the recipient of a “Sara Borrell” fellowship from ISCIII (CD09/0007); M.A.S.-G., N.L.-U., C.O-d.S.L., C.R.-M., and S.Q.-C. were recipients of an FPU fellowship from Spanish Ministry of Education, Culture, and Sport (respectively, FPU13/00530, FPU14/02115, AP2010–1598, FPU16/02050, and FPU22/00974); A.H.-G. was the recipient of an FPI fellowship from Spanish Ministry of Education, Culture, and Sport (BES-2010-033886); and B.M.-R. was the recipient of a “Junta de Andalucía” predoctoral fellowship (2021). A.E.R.-N. was recipient of JdlC-F fellowship from MCIN/AEI/10.13039/501100011033 (FJCI-2015-23708) and “Contrato de Acceso de I+D+i” from VI PPIT—Universidad de Sevilla. A.B.M.-M. was recipient of the RyC program RYC-2017-22594. J.M.B.-R. was recipient of a 2019-FPI fellowship., Peer reviewed